-$0.09 EPS Expected for Curis, Inc. (CRIS) This Quarter
Wall Street analysts predict that Curis, Inc. (NASDAQ:CRIS) will report earnings per share (EPS) of ($0.09) for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Curis’ earnings. The highest EPS estimate is ($0.08) and the lowest is ($0.10). Curis posted earnings of ($0.08) per share during the same quarter last year, which suggests a negative year over year growth rate of 12.5%. The company is expected to announce its next quarterly earnings results on Thursday, March 8th.
On average, analysts expect that Curis will report full-year earnings of ($0.41) per share for the current financial year, with EPS estimates ranging from ($0.42) to ($0.40). For the next financial year, analysts forecast that the business will post earnings of ($0.39) per share, with EPS estimates ranging from ($0.44) to ($0.31). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow Curis.
Curis (NASDAQ:CRIS) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.02). The business had revenue of $2.44 million during the quarter, compared to the consensus estimate of $2.19 million. Curis had a negative return on equity of 250.58% and a negative net margin of 629.29%. The company’s revenue was up 38.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.21) earnings per share.
Shares of Curis (NASDAQ CRIS) opened at $0.83 on Tuesday. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 1.24. Curis has a 1-year low of $0.79 and a 1-year high of $3.48.
In other Curis news, CEO Ali Ph.D. Fattaey bought 50,000 shares of the company’s stock in a transaction dated Wednesday, November 15th. The shares were purchased at an average price of $1.06 per share, for a total transaction of $53,000.00. Following the acquisition, the chief executive officer now owns 115,890 shares in the company, valued at approximately $122,843.40. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders own 4.07% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in Curis by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 4,827,625 shares of the biotechnology company’s stock valued at $13,421,000 after acquiring an additional 304,268 shares during the period. First Eagle Investment Management LLC lifted its stake in Curis by 10.4% during the 3rd quarter. First Eagle Investment Management LLC now owns 26,508,672 shares of the biotechnology company’s stock valued at $39,498,000 after acquiring an additional 2,500,000 shares during the period. Goldman Sachs Group Inc. lifted its stake in Curis by 1.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 119,638 shares of the biotechnology company’s stock valued at $226,000 after acquiring an additional 1,880 shares during the period. Bank of America Corp DE lifted its stake in Curis by 58.7% during the 1st quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock valued at $101,000 after acquiring an additional 13,448 shares during the period. Finally, Geode Capital Management LLC lifted its stake in Curis by 8.3% during the 1st quarter. Geode Capital Management LLC now owns 918,592 shares of the biotechnology company’s stock valued at $2,553,000 after acquiring an additional 70,139 shares during the period. Institutional investors own 55.22% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “-$0.09 EPS Expected for Curis, Inc. (CRIS) This Quarter” was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/12/05/0-09-eps-expected-for-curis-inc-cris-this-quarter.html.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.